Department of Clinical Laboratory, First Affiliated Hospital of Nanchang University.
Medical College of Nanchang University.
Int J Lab Hematol. 2021 Aug;43(4):693-698. doi: 10.1111/ijlh.13438. Epub 2020 Dec 29.
Long noncoding RNA maternally expressed gene 3 (MEG3) expression was significantly decreased in acute myeloid leukemia (AML). However, its expression and clinical significance in acute promyelocytic leukemia (APL) remain unclear. Thus, the present study aimed to investigate the expression of MEG3 in APL and explore its clinical value.
A total of 287 AML patients derived from The Cancer Genome Atlas (TCGA) and Vizome database were enrolled. A development and validation cohort, including APL, AML with AML1/ETO, and other types of AML patients and disease controls, from the First Affiliated Hospital of Nanchang University, were also enrolled in this study. The correlation between MEG3 expression and the clinicopathological features in APL was investigated. The diagnostic values of MEG3 expression in APL were analyzed by receiver operating characteristic (ROC) curves.
In the development set, MEG3 expression was significantly increased in APL than AML with AML1/ETO, other types of AML, and disease controls, which was consistent with the results from the database analysis. MEG3 expression in APL was associated with age (P = .0053) but did not correlate with other clinicopathological features (P > .05). ROC curve analysis in the development set and diagnostic test analysis in the validation set suggested that MEG3 expression has a significant value in the diagnosis of APL. Furthermore, the expression of MEG3 decreased during the follow-up of patients with negative PML/RARα fusion gene.
MEG3 serves as a novel marker for the diagnosis of APL, evaluates the curative effect, and provides a novel direction for further research.
长链非编码 RNA 母性表达基因 3（MEG3）在急性髓系白血病（AML）中的表达显著降低。然而，其在急性早幼粒细胞白血病（APL）中的表达及其临床意义尚不清楚。因此，本研究旨在探讨 MEG3 在 APL 中的表达及其临床价值。
共纳入 287 例来自癌症基因组图谱（TCGA）和 Vizome 数据库的 AML 患者。还纳入了南昌大学第一附属医院的一个开发和验证队列，包括 APL、AML1/ETO 伴 AML 和其他类型的 AML 患者和疾病对照者。研究了 MEG3 表达与 APL 临床病理特征的相关性。通过受试者工作特征（ROC）曲线分析 MEG3 表达在 APL 中的诊断价值。
在开发组中，APL 中 MEG3 的表达明显高于 AML1/ETO、其他类型的 AML 和疾病对照组，这与数据库分析的结果一致。APL 中 MEG3 的表达与年龄相关（P=0.0053），但与其他临床病理特征无关（P>0.05）。在开发组中的 ROC 曲线分析和验证组中的诊断试验分析表明，MEG3 表达在诊断 APL 方面具有显著价值。此外，在 PML/RARα 融合基因阴性的患者随访中，MEG3 的表达下降。
MEG3 可作为 APL 诊断的新型标志物，评估疗效，并为进一步研究提供新方向。
